Utility of the chromogenic and fluorogenic properties of benzofurazan for the assay of milnacipran in human urine and plasma

被引:16
作者
Mostafa, Islam M. [1 ]
Omar, Mahmoud A. [1 ]
Nagy, Dalia M. [1 ]
Derayea, Sayed M. [1 ]
机构
[1] Menia Univ, Fac Pharm, Dept Analyt Chem, Al Minya, Egypt
来源
RSC ADVANCES | 2018年 / 8卷 / 39期
关键词
REUPTAKE INHIBITOR; SPECTROPHOTOMETRIC DETERMINATION; HYDROCHLORIDE; STABILITY; SEROTONIN; HPLC; FORMULATIONS; BULK;
D O I
10.1039/c8ra03614d
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Our article presents the development and validation of two simple, very sensitive, and low-cost spectroscopic methods for the assay of milnacipran hydrochloride in bulk form, pharmaceutical tablets and spiked human urine and plasma. Spectroscopic methods (spectrophotometric and spectrofluorimetric techniques) were dependent on the chromogenic and fluorogenic properties of the 4-chloro-7 nitrobenzofurazan (NBD-Cl) reagent. The reaction product, resulting from the interaction between NBD-Cl and milnacipran in the presence of borate buffer pH 8.5, was measured spectrophotometrically at 465 nm and spectrofluorimetrically at 510 nm after excitation at 465 nm. The absorbance-concentration plot was rectilinear over the range of 1.5-12 g mL(-1) with a limit of quantitation 1.09 g mL(-1), while the fluorescence-concentration plot was rectilinear over the range of 0.03-0.5 g mL(-1) with a limit of quantitation 0.02 g mL(-1). Influential parameters affecting the development and stability of the reaction product were studied and optimized. Assurance of the cited drug in its tablets by our proposed methods was successfully completed without obstruction from the presence of the basic excipients with average percentage recoveries of 99.27 +/- 1.18 and 99.44 +/- 0.69 for the spectrophotometric and spectrofluorimetric methods, respectively. The spectrofluorimetric method was additionally adopted as a preliminary in vitro study for the assay of the cited drug in spiked human urine and plasma with average percentage recoveries of 101.52 +/- 1.01 and 100.38 +/- 1.57 for spiked urine and plasma, respectively.
引用
收藏
页码:22154 / 22160
页数:7
相关论文
共 21 条
  • [1] [Anonymous], 2009, The Complete Drug Reference, Martindale
  • [2] Liquid chromatography/electrospray ionization tandem mass spectrometric study of milnacipran and its stressed degradation products
    Borkar, Roshan M.
    Raju, B.
    Devrukhakar, Prashant S.
    Tondepu, Naresh
    Rao, A. B. N. Nageswara
    Srinivas, R.
    [J]. RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2013, 27 (02) : 369 - 374
  • [3] Spectrofluorimetric and TLC-densitometric methods for a stability indicating assay of valacyclovir hydrochloride in the presence of its degradation product
    Derayea, Sayed M.
    Mostafa, Islam M.
    Omar, Mahmoud A.
    [J]. RSC ADVANCES, 2014, 4 (80) : 42308 - 42315
  • [4] Simple and Sensitive Colorimetric Method for the Determination of Milnacipran in Bulk and Swellable Matrix Tablets
    Hussain, Talib
    Shahzad, Muhammad Khurram
    Hayat, Khezar
    Hussain, Khalid
    Bukhari, Nadeem Irfan
    [J]. PHARMACEUTICAL CHEMISTRY JOURNAL, 2016, 50 (05) : 346 - 352
  • [5] ICH Harmonized Tripartie Guidline Q2A, 2005, TEXT VAL AN PROC
  • [6] Stability-Indicating HPTLC Method for Determination of Milnacipran Hydrochloride in Pharmaceutical Formulations
    Khatri, Deepak Mohanlal
    Mehta, Priti Jignesh
    [J]. JPC-JOURNAL OF PLANAR CHROMATOGRAPHY-MODERN TLC, 2011, 24 (05) : 412 - 418
  • [7] Chiral analysis of milnacipran by a nonchiral HPLC - circular dichroism: Improvement of the linearity of dichroic response by temperature control
    Lecoeur-Lorin, Marie
    Delepee, Raphael
    Ribet, Jean-Paul
    Morin, Philippe
    [J]. JOURNAL OF SEPARATION SCIENCE, 2008, 31 (16-17) : 3009 - 3014
  • [8] Leo RJ, 2006, CURR OPIN INVEST DR, V7, P637
  • [9] Moffat Anthony C., 2011, CLARKES ANAL DRUGS P, Vfourthth
  • [10] Analysis of quetiapine in human plasma using fluorescence spectroscopy
    Mostafa, Islam M.
    Omar, Mahmoud A.
    Nagy, Dalia M.
    Derayea, Sayed M.
    [J]. SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2018, 196 : 196 - 201